Sarcoma Specialist:

Jason Sicklick, M.D., F.A.C.S.

Surgical Fellowship, 2009-2010

Surgical Oncologist, GIST Specialist, and Professor of Surgery and Pharmacology
UC San Diego Health
3855 Health Sciences Drive, 2313 La Jolla, CA 92093

Dr. Jason Sicklick received his medical degree from the UCLA School of Medicine, completed his general surgery residency at The Johns Hopkins Hospital where he was the Administrative Chief Resident, and completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center where he was the Chief Administrative Fellow. He joined the UC San Diego Division of Surgical Oncology at Moores Cancer Center in 2010. He is an NIH and FDA R01 funded investigator, Professor of Surgery, Executive Vice Chair of Research in the Department of Surgery, and Co-Leader of the Sarcoma Disease Team at the UC San Diego Moores Cancer Center. He is a board-certified general surgeon and surgical oncologist specializing in the treatment of complex retroperitoneal and abdominal sarcomas, including gastrointestinal stromal tumors (GIST), as well as hepatobiliary oncology. In 2016, Dr. Sicklick was named the GIST Clinician of the Year by the Life Raft GIST Support Group, the largest GIST patient advocacy group in the world. In 2018, Dr. Sicklick was selected as a James IV Association of Surgeons fellow. This highly prestigious international traveling fellowship is designed to promote communication and collaboration in the international surgical community. In 2018 he also received the RARE Champion of Hope in Medical Care & Treatment Award from the Global Genes-Allies in Rare Disease, the largest global non-profit advocacy organization for individuals and families fighting rare and genetic diseases. In addition, he received the 2019 Excellence in Mentoring Award from the UC San Diego Health Systems International. In 2021, he received the Rare Impact Award from the National Organization for Rare Disorders (NORD®), as well as the UC San Diego Foundation’s 2021 Excellence in Stewardship Award (campus-wide award). Dr. Sicklick is currently an active member of the National Comprehensive Cancer Network (NCCN) Soft Tissue Sarcoma Committee and GIST Subcommittee, and the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG), amongst several national/international committees that he currently serves on. He also serves on the medical advisory boards of Global Genes and The Life Raft Group, as well as co-chairs Study Section Panel B (Translational) of the Israel Cancer Research Fund and serves on their International Scientific Council. Most recently, he initiated and chairs the monthly TARPSWG International Tumor Board to convene retroperitoneal sarcoma experts (surgical oncologist, medical oncologists, radiation oncologists, orthopedic oncologists) from around the world to discuss cases focused on borderline/unresectable retroperitoneal sarcomas. Dr. Sicklick has been featured in many lay press articles, including stories in ABC News, National Geographic, the Los Angeles Times, and the San Diego Union Tribune. His translational and clinical research focus on molecular mechanisms of GIST, as well as precision medicine approaches to cancer therapy for advanced cancers.